OR WAIT null SECS
Through the acquisition, Sanofi will have access to Kiadis’ proprietary platform, which uses natural killer cells from a healthy donor to make products for a wide range of patients across several indications.
Sanofi announced on Nov. 2, 2020 that it is acquiring Kiadis, a Netherlands-based clinical-stage biopharmaceutical company focused on developing natural killer (NK) cell-based medicines for the treatment of life-threatening diseases, for $360 million.
Through the acquisition, Sanofi will have access to Kiadis’ proprietary platform, which uses NK cells from a healthy donor to make products for a wide range of patients across several indications, a Sanofi press release said.
“We believe the Kiadis ‘off the shelf’ K-NK cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches,” said John Reed, MD, PhD, global head of Research & Development at Sanofi, in the press release.
“Kiadis’ vision is to bring novel cell-based medicines to people with life-threatening diseases, and this transaction will help achieve that vision,” said Arthur Lahr, CEO of Kiadis, in the press release. “Sanofi’s offer is a clear testimony to the uniqueness of our NK-cell platform and the rapid success of Kiadis’ transformation. The Kiadis Boards unanimously believe that Sanofi has the resources and financial strength to accelerate development of our NK-cell products, to the benefit of patients. We believe this transaction represents compelling value to shareholders and offers a fair reflection of the potential of our platform and pipeline, given the risk/reward profile typical to biotech and the capital required to execute our business plan. Finally, this transaction will provide excellent career opportunities for our employees, who will be viewed by Sanofi as their internal cell-therapy experts.”